Sponsor

The Clatterbridge Cancer Centre NHS Foundation Trust

Clinical research sponsor

Published trials8
Recruiting shown2
Roles2
SourceClinicalTrials.gov

Clinical trials

8 shown
HER2+ CNS SurveillanceNCT07748598 · lead sponsor · 2025-10-03
RECRUITING
Monitoring Treatment Response With Urine and Serum Metabolome Markers in Patients Treated With Novel Hormone Therapy and Have Either Hormone Sensitive Metastatic Prostate Cancer or Disease Progression on Treatment.NCT07837063 · lead sponsor · 2026-09-01
NOT_YET_RECRUITING
CCP Cancer UK Companion StudyNCT04603105 · lead sponsor · 2021-02-28
ACTIVE_NOT_RECRUITING
Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical OutcomeNCT04622761 · lead sponsor · 2021-01-15
UNKNOWN
Investigation of an Abdominal Compression DeviceNCT04270890 · lead sponsor · 2018-06-21
UNKNOWN
Magnetic Resonance Imaging for Lung RadiotherapyNCT04275921 · lead sponsor · 2018-05-16
UNKNOWN
BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate CancerNCT02125175 · lead sponsor · 2014-01-01
COMPLETED
SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus No SurveillanceNCT07503717 · collaborator · 2025-06-01
RECRUITING

Sponsor roles

lead sponsor7
collaborator1

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.